Clinical Trial – Page 3

Immunogenicity and safety of an Escherichia coli-produced 9-valent human papillomavirus vaccine (types 6/11/16/18/31/33/45/52/58) in healthy Chinese women aged 20–45 years: a single-center, randomized, observer-blinded, positive controlled phase 2 clinical trial

14 de November de 2025 by Mingwei Wei

BackgroundVaccination with prophylactic human papillomavirus (HPV) vaccines is one of the most effective measures to prevent cervical cancer and other related diseases. Here we aimed to evaluate the immunogenicity and safety of an Escherichia coli-prod…

Immunomodulatory effects and mechanisms of Qi-Xu-Tiao-Ti formula in Qi-deficiency constitution: a randomized controlled trial integrated with multi-omics and network pharmacology analysis

31 de October de 2025 by Renyun Cui

BackgroundThe Qi-deficiency constitution (QDC) is a body constitution type characterized by weakened immune function and increased susceptibility to infectious diseases. Emerging evidence indicates that Chinese herbal medicine can effectively improve i…

Weizmannia coagulans BC99 regulates oxidative stress and serum metabolic pathways to improve allergic rhinitis: a randomized, double-blind, placebo-controlled trial

24 de October de 2025 by Xuan Li

BackgroundProbiotics have demonstrated potential application value in alleviating allergic diseases, but their mechanisms of action remain to be explored. This study aimed to investigate the clinical efficacy of probiotics in patients with allergic rhi…

Weizmannia coagulans BC99 regulates oxidative stress and serum metabolic pathways to improve allergic rhinitis: a randomized, double-blind, placebo-controlled trial

24 de October de 2025 by Xuan Li

Weizmannia coagulans BC99 regulates oxidative stress and serum metabolic pathways to improve allergic rhinitis: a randomized, double-blind, placebo-controlled trial

24 de October de 2025 by Xuan Li

Safety, tolerability, and immunogenicity of INO-4500, a synthetic DNA-based vaccine against Lassa virus, in a phase 1b clinical trial in healthy Ghanaian adults

24 de October de 2025 by Kwadwo Ansah Koram

BackgroundLassa fever (LF) is an acute viral hemorrhagic illness endemic to West Africa, with no licensed vaccines or targeted treatments available, highlighting a critical gap in global health preparedness. T cell-mediated immunity plays a central rol…

Trends in allergen-reactive CRTH2+ T cells and TARC associated with successful outcomes in a phase 2 cashew oral immunotherapy study

22 de October de 2025 by Sayantani B. Sindher

BackgroundWe designed an oral immunotherapy (OIT) clinical trial for cashew allergy to further our understanding of immunological responses with treatment, including changes in allergen-specific T cells. This information can further assist with the des…

Integrated metabolomic insights into the mechanism of Bacillus coagulans in enhancing intestinal recovery following gynecological laparoscopic surgery: a randomized clinical trial

26 de September de 2025 by Juan Xu

ObjectiveTo evaluate the efficacy and mechanistic underpinnings of live Bacillus coagulans tablets in accelerating recovery of intestinal function after gynecologic laparoscopic surgery.MethodsA randomized, double-blind, placebo-controlled trial includ…

No evidence of MMR induced trained immunity to prevent SARS COV2: results from a multi-centre RCT

16 de September de 2025 by Sinead Delany-Moretlwe

BackgroundMeasles-containing vaccines (MCV), by training innate immune cells, are hypothesized to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19).MethodsIn this international, doubl…

Preliminarily evaluation the safety and immunogenicity of tetanus, reduced diphtheria and acellular pertussis (five components) combined vaccine, adsorbed (Tdcp) in participants aged 6 years and above: a blinded and randomised, and controlled phase I clinical trial

5 de September de 2025 by Xiaoyu Liu

Pertussis remains a significant global public health challenge, particularly in China, where no licensed pertussis-containing vaccines are available for individuals aged 6 years and older. This blind, randomised, and controlled phase I clinical trial e…